Centers | ||
|
|
|
UCSC Chemical Screening Center | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Therapeutic Accelerator Program (TAP) |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Test |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all Sanofi and MIT Form New Partnership to Foster Industry - Academic CollaborationSanofi and MIT's Center for Biomedical Innovation has established a new partnership to foster basic and applied research and develop solutions to address unmet clinical needs. Sanofi will be providing funding to support specific research projects... View all |
No EVENTS for listing |
No Job Posts |
